Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial

Ramos, Paulo Mueller; Sinclair, Rodney; Kasprzak, Michał; Miot, Hélio Amante

doi:10.1016/j.jaad.2019.08.060

Cited by 92 publications

(109 citation statements)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Individual patient data including sex, dose of OM received, presence of hypertrichosis and presence of lower limb edema were collected and synthesized in the pooled-analysis. These data were available for the studies of Pirmez et al, 4 Lueangarun et al, 5 Ramos et al, 6 Sinclair et al, 7 Beach et al 8 For studies that used more than one dose of OM, data of adverse effects for each dose and sex subgroups were obtained by contacting the authors (Jimenez-Cauhe et al, 9 Rodrigues-Barata et al, 10 and Wambier et al 11 Aggregated meta-analysis of therapeutic response rate to OM could not be performed because (a) different hair diseases were treated in each study; (b) studies used heterogeneous criteria for the assessment of therapeutic hair regrowth; and (c) a large number of patients did not receive OM in monotherapy.…”

Section: Data Synthesis and Outcomesmentioning

confidence: 99%

Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data

Jimenez‐Cauhe

Saceda‐Corralo

Rodrigues‐Barata

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

low dose oral minoxidil (OM) is an increasingly used treatment for androgenetic alopecia and other types of hair loss. to analyze available data of patients treated with OM, focusing on safety and adverse effects. a search in PubMed and EMBASE was performed for studies reporting the treatment of alopecia with OM. Individual patient data available for pooled-analysis were sex, dose of OM, presence of hypertrichosis and lower limb edema. 14 studies including 442 patients were analyzed. OM was used at doses between 0.25 and 5 mg, for eight different types of alopecia. Hypertrichosis was observed in 24% of patients. All doses had an increased odds ratio of hypertrichosis, compared to 0.25 to 0.5 mg (P < .001). Pedal edema was observed in 2% and was also associated with higher doses of OM (P = .009). Postural hypotension and heart rate alterations occurred only in 1.1% and 1.3% of the patients, respectively. Efficacy of OM could not be analyzed due to heterogeneous studies. However, four studies using OM for androgenetic alopecia reported a clinical response in 70% to 100% of the patients. Low dose OM is a safe and well-tolerated treatment for hair loss, presenting a lower adverse effect rate than standard doses.

show abstract

Section: Data Synthesis and Outcomesmentioning

confidence: 99%

Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data

Jimenez‐Cauhe

Saceda‐Corralo

Rodrigues‐Barata

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Recent studies have investigated the efficacy of low-dose oral minoxidil (0. effluvium, and monilethrix, with promising results shown including increased hair thickness in LPP. [65][66][67][68] Although no studies have been published to date on the efficacy of oral minoxidil for FFA, it is nevertheless a potential consideration for adjunctive therapy, particularly if the FFA is unmasking androgenetic alopecia. Future studies are needed to investigate the efficacy of oral minoxidil specifically for patients with FFA.…”

Section: Oral Minoxidilmentioning

confidence: 99%

<p>Optimal Management of Frontal Fibrosing Alopecia: A Practical Guide</p>

Imhof

Tolkachjov²

2020

CCID

View full text Add to dashboard Cite

Frontal fibrosing alopecia (FFA) is a primary lymphocytic cicatricial alopecia that is often considered a clinical variant of lichen planopilaris (LPP) due to their shared histopathologic features. FFA is characterized by the recession of the frontal, temporal, or frontotemporal hairline; the clinical pattern is distinct and usually includes eyebrow hair loss, as well as other associated symptoms. Pruritus, facial papules, eyelash loss, body hair involvement, and trichodynia may also occur in addition to the frontotemporal recession and eyebrow loss classically seen. Early diagnosis and prompt treatment are critical as FFA is a progressive disorder that can result in permanent hair loss. FFA is challenging as patients may not present or be recognized until the disease has progressed. Additionally, there is currently no consensus or standard treatment regimen for FFA. While many different therapies have been reported as beneficial, there are a limited number of published guidelines for the treatment of FFA. This article is a review of the literature on treatment modalities for FFA and the objective is to offer a practical guide for clinicians on the evidence-based management options currently available in the literature.

show abstract

“…Furthermore, there is an increase in hair thickness at 24 weeks compared to the baseline T A B L E 2 Main trichoscopic results expressed in mean (SD) of the comparative effectiveness of oral minoxidil for 24 weeks in the frontal area and vertex area for the treatment of FPHL AGA in patients of both sexes. 1,2,6 In our study, the majority of premenopausal or postmenopausal patients with AGA who had been treated with OM at 1.5 to 2 mg/d for more than 24 weeks had achieved excellent results. In particular, there was a statistically significant improvement in the frontal area of the total average hair density per unit area and of the total number of hairs in a 0.903-cm 2 area at 24 weeks compared to the baseline.…”

Section: Discussionmentioning

confidence: 55%

Efficacy and safety of oral minoxidil in female androgenetic alopecia

Vastarella

Cantelli

Patrì

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Oral minoxidil (OM) has been reported to be effective for androgenetic alopecia (AGA). In this retrospective study, we share our experience of using OM for >24 weeks in 12 patients with female AGA (Ludwig scale I-3-III). Twelve women (aged 18-66 years; mean age 36.66 ± 18.79 years) with AGA (Ludwig scale I-3-III) were recruited. The starting dose of minoxidil was 0.50 mg daily; at 3 months, the dose was increased to 1.50 to 2 mg daily. Efficacy outcome measures were evaluated at baseline and after 24 weeks and included global clinical photography, quantitative digital videotrichoscopic assessment and quality-of-life evaluation. An overall improvement of 38% and 23% in hair density in the frontal and vertex area, respectively, was observed after 24 weeks. The quantitative digital videotrichoscopic evaluation highlighted a statistically significant improvement in the frontal area of the total average hair density and of the total number of hairs per unit area at 24 weeks

show abstract

Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial

Cited by 92 publications

References 5 publications

Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data

Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data

<p>Optimal Management of Frontal Fibrosing Alopecia: A Practical Guide</p>

Efficacy and safety of oral minoxidil in female androgenetic alopecia

Contact Info

Product

Resources

About